Gilead's Bictegravir-Lenacapavir Once-Daily HIV Regimen Granted Priority Review

Gilead's bictegravir-lenacapavir once-daily HIV therapeutic regimen has been designated for FDA priority review, signaling simplified treatment option expansion.